Texas Medical Center Appoints Ferran Prat to Board of Directors
Texas Medical Center (TMC) announced the appointment of Ferran Prat, chief commercial officer at BostonGene, to its Board of Directors.
“Ferran Prat has an exceptional record of building strategic partnerships across leading research institutions and biotech companies,” said William McKeon, president and CEO of Texas Medical Center. “His insight into translational science and commercialization will enhance our strategy to move discoveries from the lab to the patient more efficiently.”
Prat is a life sciences executive with extensive experience in strategy, licensing, and company formation across therapeutics, diagnostics, and medical devices. He previously served as senior vice president of Research Administration and Industry Relations at MD Anderson Cancer Center, where he helped drive industry collaborations and translational research.
His leadership experience includes serving as Geschäftsführer at Adnagen GmbH, board member at Syena, Vescor Therapeutics, CTMC, and OncoResponse Inc., chairing the Life Sciences chapter of the Greater Houston Partnership, and co-founding Cancer Focus Fund I and II.
“Texas Medical Center is uniquely positioned to accelerate discoveries that redefine the standard of care for patients everywhere,” said Prat. “I look forward to strengthening collaboration among TMC’s member institutions, industry partners, and leading scientific minds to help bring new therapies from concept to clinic.”
Prat holds a Ph.D. in Chemistry from UCLA, a J.D. in Law from the University of San Diego (magna cum laude), and a B.S. in Chemical Engineering from IQS-Barcelona.
Prat is one of two new members appointed to the TMC Board of Directors. Gretchen Watkins, former president of Shell USA, was also announced as a new board member.
The full list of members of the Texas Medical Center Board of Directors can be found at www.tmc.edu/about-tmc/leadership/
###
About Texas Medical Center (TMC): TMC is the world’s most comprehensive life science ecosystem. At the forefront of advancing life sciences, TMC is on a mission to further accelerate the pace of healing by harnessing its collective expertise in innovation, research, development, production, and patient care – all within a single, centralized medical ecosystem. With over 70+ million square feet and 120,000+ employees, TMC is leveraging its collective power by pioneering a revolutionary life sciences initiative that encompasses the entire treatment life cycle, from discovery to delivery, within a single, world-class medical complex, on a scale never before seen.